ISOFOL — Isofol Medical AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK259.28m
- SEK144.45m
Brief: Isofol Medical Q4 Net Income SEK 13.102 Million
Brief: Isofol Medical Q3 Loss For Period Widens To SEK 10.9 Mln
Brief: Isofol Medical Q3 Net Income SEK -10.859 Million
Brief: Isofol Strengthens Outlook For Further Extending Patent Protection Of Its Drug Candidate Arfolitixorin
Brief: Isofol Medical Q2 Loss Widens To SEK 11 Mln
Brief: Isofol Medical Q2 Net Income SEK -11.045 Million
Brief: Isofol Appoints Magdalena Hagman As New CFO
Brief: Isofol Announces New Preclinical Data Supporting Development Plan For Arfolitixorin
Brief: Isofol Posts New Study Results In Favor Of Arfolitixorin
Brief: Isofol Medical CFO To Leave Company
Brief: Isofol Medical Q1 Net Income SEK -8.482 Million
Brief: Isofol Medical Proposes That No Dividend Will Be Paid For 2023
Brief: Isofol Medical Q4 Net Income SEK -8.883 Million
Brief: Isofol's BOD To Initiate Planning Of Clinical Studies
Brief: Isofol Announces Appointment of Magnus Hurst As New Chief Financial Officer
Brief: Isofol Appoints Petter Segelman Lindqvist As New CEO
Brief: Isofol Medical EGM Resolved New Board Composition With Jan-Eric Österlund As Chairman
Brief: Isofol Medical Says All Board Members To Leave Positions If Jan-Eric Österlund Elected BoD Member
Brief: Isofol Says Has Received First Results From Laboratory Tests Of Arfolitixorin